Congestive Heart Failure & Angina

Chronic low-grade inflammation has emerged as a central driver of both angina and heart failure. Beyond classical ischemic mechanisms, inflammatory mediators contribute to endothelial dysfunction, microvascular instability, and myocardial injury. Cytokines such as TNF-α, IL-6, and CRP have been implicated in adverse remodeling, while immune cell infiltration accelerates fibrosis and impairs contractility. Evidence also suggests that persistent immune activation worsens plaque instability, linking inflammation to both acute coronary syndromes and progression to heart failure.

Recent trials targeting inflammation—such as IL-1β blockade in CANTOS—demonstrate the potential of anti-inflammatory strategies in reducing cardiovascular risk. Ongoing research is evaluating immune-modulatory drugs, including colchicine, JAK-STAT inhibitors, and novel biologics, for their cardioprotective potential. This track will explore how fine-tuning immune responses may prevent angina progression, improve outcomes in established heart failure, and integrate with standard therapies. The session will also emphasize biomarkers of inflammation for patient stratification and discuss translational challenges in balancing immunosuppression with the risk of infection.

The healthy heart relies predominantly on fatty acid oxidation for energy, but in heart failure, metabolic remodeling shifts substrate utilization toward glucose and ketone metabolism. While this adaptation may initially preserve ATP production, over time, metabolic inflexibility worsens contractile dysfunction, oxidative stress, and mitochondrial inefficiency. Disruptions in nutrient signaling pathways, including AMPK and mTOR, further exacerbate the energy deficit characteristic of failing myocardium.

Targeting metabolic remodeling offers a novel therapeutic window. SGLT2 inhibitors have redefined heart failure management not only through diuresis but also by favorably altering myocardial energetics and promoting ketone utilization. Other approaches under study include metabolic modulators like trimetazidine, agents enhancing mitochondrial biogenesis, and gene therapies targeting defective oxidative pathways. This track will present insights into metabolic shifts in heart failure, highlight breakthroughs in metabolic-targeted drugs, and discuss how precision strategies may restore energetic balance and improve functional capacity in patients.

Coronary microvascular dysfunction (CMD) has emerged as a critical mechanism underlying angina in patients with non-obstructive coronary artery disease (ANOCA/INOCA). Unlike epicardial stenosis, CMD results from impaired vasodilation, endothelial dysfunction, and structural remodeling of the microcirculation, leading to inadequate myocardial perfusion during stress. Patients often present with typical angina but lack significant blockages on angiography, making diagnosis challenging. CMD not only affects quality of life but also confers an increased risk of heart failure with preserved ejection fraction (HFpEF).

Advances in non-invasive imaging—such as PET, cardiac MRI, and invasive coronary flow reserve (CFR) measurements—are improving CMD detection. Therapeutic strategies are evolving, ranging from endothelial-targeted agents (statins, ACE inhibitors) to novel vasodilators and lifestyle interventions. This track will examine diagnostic innovations, mechanistic insights, and tailored therapies for CMD. Discussions will focus on closing gaps in recognizing and managing angina without obstructive coronary disease, an area increasingly relevant to women and elderly populations.

Myocardial fibrosis is a hallmark of adverse remodeling in both ischemic and non-ischemic heart disease. It results from an imbalance between extracellular matrix synthesis and degradation, driven by fibroblast activation, transforming growth factor-beta (TGF-β) signaling, and chronic neurohormonal and inflammatory stimuli. Fibrosis stiffens the myocardium, impairs diastolic function, disrupts electrical conduction, and predisposes patients to arrhythmias. Importantly, the extent of fibrosis correlates with prognosis across the spectrum of cardiomyopathies.

Cardiac MRI with late gadolinium enhancement and T1 mapping has revolutionized fibrosis detection, enabling precise quantification and risk stratification. Therapeutic efforts are shifting toward anti-fibrotic strategies, including mineralocorticoid receptor antagonists, TGF-β pathway inhibitors, and emerging molecular therapies. This track will highlight the mechanistic underpinnings of fibrosis, diagnostic advances, and translational therapies that aim not only to halt but potentially reverse fibrotic remodeling. Attendees will gain insights into how targeting fibrosis could reshape outcomes in heart failure and angina populations.

Right heart failure is a complex clinical entity, frequently driven by pulmonary hypertension (PH) that places an excessive load on the right ventricle (RV). Unlike left-sided failure, RV dysfunction is less understood yet strongly predictive of poor prognosis. Chronic pressure overload leads to maladaptive hypertrophy, dilatation, and progressive RV-arterial uncoupling. PH may stem from left-sided disease, lung pathology, or pulmonary arterial hypertension, but regardless of etiology, the interplay between pulmonary vascular resistance and RV contractility determines clinical outcomes.

Advancements in PH-targeted therapies—including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues—offer opportunities to reduce RV afterload and improve survival. Novel imaging approaches, hemodynamic monitoring, and biomarkers are enhancing risk stratification in RV failure. This track will address the dual challenges of managing right heart dysfunction and PH, highlight evolving pharmacological and interventional options, and emphasize the need for integrated care models. Participants will also explore emerging regenerative and device-based therapies aiming to directly support RV performance

Strain imaging, based on speckle-tracking echocardiography, has transformed cardiac assessment by quantifying subtle myocardial deformation beyond traditional ejection fraction measurements. Global longitudinal strain (GLS) provides sensitive detection of early systolic dysfunction in patients with heart failure, cardiotoxic chemotherapy exposure, and valvular disease. Unlike EF, which often remains preserved until late in disease, strain abnormalities can identify subclinical dysfunction, offering a window for earlier intervention.

Clinical integration of strain imaging is expanding rapidly, with applications in heart failure phenotyping, risk stratification, and monitoring treatment response. Advances in 3D strain and layer-specific analysis enhance precision, while artificial intelligence is improving reproducibility. This track will explore the latest developments in echocardiographic strain, including its role in HFpEF diagnosis and perioperative risk evaluation. Attendees will gain insights into practical implementation, limitations, and future directions where strain-based metrics may guide personalized management strategies for cardiovascular patients

Molecular imaging enables visualization of biological processes at the cellular and molecular level, bridging the gap between pathophysiology and clinical care. In cardiovascular disease, molecular probes can detect inflammation, apoptosis, angiogenesis, and fibrosis—key processes underlying heart failure and ischemic syndromes. Techniques such as PET and SPECT imaging, combined with novel radiotracers, allow non-invasive mapping of disease activity that precedes structural changes visible on conventional imaging.

The field is rapidly evolving, with applications in early detection of vulnerable plaques, guiding targeted therapies, and assessing novel drug efficacy. Hybrid modalities like PET/MRI provide complementary insights into both functional and structural changes. This track will highlight cutting-edge molecular imaging advances, discuss translational hurdles, and showcase how precision imaging could revolutionize diagnosis and treatment in angina and heart failure. Attendees will learn how molecular signatures may eventually guide patient-specific therapeutic decisions and improve long-term outcomes.

Cardiac CT angiography (CCTA) has become a frontline tool for non-invasive assessment of coronary arteries, offering high-resolution visualization of luminal stenosis and plaque morphology. Beyond anatomical imaging, advances in CT perfusion and fractional flow reserve CT (FFR-CT) provide functional insights into ischemia. However, the interpretation of vast imaging datasets presents challenges, opening opportunities for artificial intelligence (AI) integration. AI-driven algorithms enhance image reconstruction, automate plaque quantification, and improve risk stratification by identifying high-risk features invisible to human observers.

Recent studies suggest that AI-assisted CCTA can improve diagnostic accuracy, predict clinical outcomes, and reduce unnecessary invasive procedures. This track will explore the transformative role of AI in angiography, covering applications in rapid diagnosis, longitudinal monitoring, and precision treatment planning. Ethical and logistical considerations, including data validation and integration into clinical workflows, will also be addressed. Participants will gain an understanding of how AI-enabled cardiac CT may soon redefine the standard of care in coronary artery disease evaluation.

Accurate hemodynamic assessment is critical in managing heart failure, guiding therapy, and predicting decompensation. Traditionally, invasive right heart catheterization has been the gold standard; however, the risks and limited accessibility necessitate non-invasive alternatives. Emerging modalities—including Doppler echocardiography, impedance cardiography, and wearable biosensors—now allow continuous or serial monitoring of cardiac output, filling pressures, and systemic vascular resistance without invasive procedures.

Integration of non-invasive monitoring with digital health platforms enables remote patient management, offering real-time alerts for impending decompensation and reducing hospitalizations. Next-generation devices employing AI analytics further refine predictive accuracy. This track will present current and emerging technologies for hemodynamic monitoring, their validation against invasive standards, and their role in both acute and chronic heart failure care. Attendees will also discuss challenges of adoption, reimbursement models, and opportunities for personalized medicine through continuous physiologic tracking

Circulating microRNAs (miRNAs) have emerged as powerful biomarkers in cardiovascular disease, reflecting gene regulatory changes involved in myocardial stress, remodeling, and apoptosis. Unlike conventional biomarkers such as BNP or troponins, miRNAs offer insights into molecular pathways driving disease progression. Studies have identified specific miRNA signatures associated with heart failure, angina, and myocardial infarction, suggesting their potential role in early diagnosis and prognosis. Moreover, their stability in plasma and non-invasive detectability make them attractive candidates for routine clinical use.

Beyond miRNAs, novel biomarkers including galectin-3, ST2, and growth differentiation factor-15 are reshaping diagnostic and risk stratification frameworks. These markers not only predict adverse outcomes but also serve as therapeutic targets in clinical trials. This track will delve into the clinical translation of miRNAs and emerging biomarkers, discussing assay standardization, regulatory challenges, and integration with existing diagnostic platforms. Attendees will gain an understanding of how biomarker-driven precision medicine could redefine cardiovascular care.

The global burden of cardiovascular disease disproportionately affects low- and middle-income countries, where access to advanced diagnostics is limited. Point-of-care (POC) technologies, such as portable echocardiography, handheld ECG devices, and rapid biomarker assays, offer scalable solutions for early detection and monitoring. These innovations reduce diagnostic delays, improve triage, and facilitate decentralized care delivery, particularly in rural and underserved populations.

Recent advances in miniaturization, connectivity, and affordability are driving the expansion of POC tools. Integration with mobile health platforms enables real-time data transmission and teleconsultation, bridging gaps in specialist access. This track will highlight successful models of POC implementation, discuss challenges in training and infrastructure, and evaluate policy-level strategies for sustainability. The session will emphasize how POC diagnostics can empower frontline healthcare workers and transform cardiovascular care equity worldwide.

Platelet activation and thrombus formation are central mechanisms in coronary artery disease and heart failure-related events. While dual antiplatelet therapy (DAPT) and anticoagulants remain the standard, bleeding risks and variable responses necessitate novel approaches. Next-generation antiplatelet drugs, including reversible P2Y12 inhibitors and protease-activated receptor antagonists, are being developed to optimize efficacy while reducing adverse effects. Similarly, direct oral anticoagulants (DOACs) continue to evolve, offering simplified dosing and superior safety compared to traditional vitamin K antagonists.

Emerging research focuses on personalized antithrombotic strategies guided by genetic testing, platelet function assays, and AI-driven risk models. Novel combination regimens and drug-eluting technologies may further refine therapy for high-risk patients. This track will provide insights into the latest advances in thrombosis management, highlighting ongoing clinical trials, real-world outcomes, and strategies for balancing ischemic protection with bleeding risk. Attendees will gain perspective on how next-generation therapies could reshape cardiovascular intervention protocols.

Dyslipidemia is a well-established risk factor for atherosclerotic cardiovascular disease, and while statins remain the cornerstone of therapy, residual risk persists for many patients. The advent of novel lipid-lowering agents—including PCSK9 inhibitors, bempedoic acid, and ANGPTL3 inhibitors—offers potent LDL reduction beyond statin therapy. Additionally, therapies targeting triglyceride-rich lipoproteins and lipoprotein(a) are under active development, aiming to address previously untreatable risk factors.

Recent outcome trials have demonstrated substantial event reduction with these agents, particularly in high-risk populations. Beyond LDL lowering, attention is turning toward pleiotropic effects such as plaque stabilization and inflammation reduction. This track will explore the expanding therapeutic landscape, discuss barriers to access and cost-effectiveness, and examine integration into treatment guidelines. Participants will also gain insights into ongoing clinical trials that could redefine lipid management strategies in the coming decade.

RNA-based therapies—including antisense oligonucleotides, small interfering RNAs (siRNAs), and messenger RNA (mRNA) platforms—are revolutionizing medicine by enabling precise modulation of gene expression. In cardiology, these approaches offer opportunities to silence harmful proteins (such as PCSK9) or restore beneficial ones. Recent approvals of siRNA-based lipid-lowering drugs have validated this therapeutic class, while preclinical studies are exploring applications in arrhythmias, myocardial regeneration, and fibrosis reduction.

The flexibility of RNA therapeutics allows rapid adaptation to new targets, but challenges remain in delivery, durability, and off-target effects. Nanoparticle-based carriers and tissue-specific delivery systems are being refined to optimize cardiac uptake. This track will highlight breakthroughs in RNA-based therapies, discuss lessons learned from other fields such as oncology, and explore their future role in cardiovascular medicine. Attendees will gain perspective on how genetic precision could complement conventional pharmacology in managing heart failure and ischemic disease.

Heart failure is increasingly recognized as an immune-mediated syndrome, where persistent low-grade inflammation contributes to myocardial injury, remodeling, and progression. Activated immune cells release cytokines such as IL-1, IL-6, and TNF-α, which disrupt cardiomyocyte function and promote fibrosis. This paradigm has sparked interest in immunomodulation as a therapeutic strategy, complementing traditional neurohormonal blockade.

Recent clinical trials, such as those testing IL-1β inhibitors and colchicine, have shown promise in reducing cardiovascular events, suggesting that targeted immune modulation could alter disease trajectory. Emerging approaches include monoclonal antibodies, JAK-STAT inhibitors, and novel cell-based therapies designed to recalibrate maladaptive immune responses. This track will examine the interplay between inflammation and heart failure progression, highlight therapeutic breakthroughs, and explore challenges such as infection risk and patient selection. Attendees will gain insights into how immunotherapy may redefine heart failure management in the near future.

Traditional cardiac rehabilitation (CR) has proven effective in improving functional capacity, reducing rehospitalization, and enhancing quality of life. Yet, participation rates remain suboptimal due to barriers such as travel, cost, and limited program availability. The emergence of digital and virtual rehabilitation models—delivered via mobile apps, telehealth platforms, and wearable devices—offers a transformative solution to expand access.

These next-generation CR programs integrate exercise prescriptions, remote monitoring, behavioral coaching, and personalized feedback, enabling patients to engage from home. Early studies demonstrate comparable outcomes to in-person programs, with additional benefits in adherence and scalability. This track will discuss the design and implementation of digital CR, regulatory and reimbursement frameworks, and strategies to integrate hybrid care models. The session will also explore how AI and gamification could enhance patient motivation, ushering in a new era of cardiac rehabilitation.

Medication non-adherence and inadequate self-management remain major contributors to poor outcomes in heart failure and angina. Complex regimens, side effects, and psychosocial factors often undermine treatment continuity. Empowering patients through education, shared decision-making, and digital tools is essential for long-term success.

Innovative approaches include reminder-based technologies, mobile health apps, and community-based support networks that foster sustained engagement. Health literacy and cultural sensitivity also play pivotal roles in designing effective interventions. This track will explore evidence-based strategies to improve adherence, highlight the role of digital platforms in patient empowerment, and discuss how healthcare teams can foster self-management skills. Attendees will gain practical insights into integrating behavioral science and technology to enhance outcomes across diverse patient populations.

Digital twin technology—virtual replicas of individual patients that simulate cardiovascular physiology—represents a groundbreaking approach in precision medicine. By integrating multimodal data, including imaging, genomics, and wearable sensor outputs, digital twins can model disease progression, predict therapy response, and optimize treatment strategies in real time.

Applications in cardiology include predicting arrhythmia risk, assessing heart failure progression, and testing interventional outcomes before procedures. This track will highlight pioneering research in creating patient-specific digital twins, discuss the role of AI and computational modeling, and explore regulatory and ethical considerations. Attendees will gain an understanding of how digital twins could revolutionize personalized cardiovascular care, enabling clinicians to anticipate complications and tailor therapies with unprecedented accuracy.

The explosion of digital health records, wearable data, and AI-driven analytics has created new challenges in ensuring privacy, security, and interoperability. Blockchain technology offers a decentralized solution, enabling secure, tamper-proof, and transparent data exchange between stakeholders in cardiovascular care. By giving patients greater control over their health information, blockchain fosters trust and facilitates research collaborations without compromising confidentiality.

Use cases in cardiology include secure sharing of imaging data, integration of remote monitoring streams, and streamlined clinical trial data management. Smart contracts further allow automated consent management and real-time audit trails. This track will examine the technical foundations of blockchain, highlight pilot projects in healthcare, and discuss barriers such as scalability and regulation. Participants will explore how blockchain could underpin the next generation of secure, patient-centered cardiovascular data ecosystems.

Nanomedicine offers a revolutionary platform for addressing the challenges of conventional cardiovascular therapies, such as systemic toxicity, poor bioavailability, and lack of tissue specificity. By engineering nanoparticles that can selectively target diseased myocardium or atherosclerotic plaques, researchers are developing precision drug delivery systems. These nanocarriers can encapsulate small molecules, biologics, or RNA-based therapies, ensuring sustained release and enhanced therapeutic efficiency.

Emerging applications include nanoparticles delivering anti-fibrotic drugs directly to scarred myocardium, lipid-based carriers improving statin delivery to plaques, and nanostructures designed for regenerative therapies. Beyond treatment, theranostic nanoparticles can combine imaging and therapy, enabling real-time monitoring of therapeutic response. This track will explore recent breakthroughs in cardiac nanomedicine, translational challenges, and regulatory considerations. Attendees will gain insights into how nanotechnology could reshape cardiovascular therapy by providing safer, more effective, and patient-specific interventions.

Monitoring intracardiac and pulmonary artery pressures is critical in preventing decompensation in heart failure patients. Next-generation implantable hemodynamic sensors provide continuous, real-time data, allowing clinicians to intervene before clinical deterioration. Unlike older technologies, these miniaturized sensors are wireless, battery-free, and compatible with digital health platforms for remote monitoring.

Clinical trials with pulmonary artery pressure sensors have already demonstrated reductions in heart failure hospitalizations, validating their utility. Ongoing innovations focus on expanding sensor capabilities, integrating multiparametric monitoring, and enhancing durability. This track will discuss the evolution of implantable sensors, their clinical impact, and future directions in predictive monitoring. Attendees will explore how sensor-driven management could redefine chronic heart failure care, enabling proactive, data-guided treatment adjustments that improve outcomes and quality of life.

Virtual reality (VR) and augmented reality (AR) are transforming both education and patient care in cardiology. In training, VR-based simulations allow clinicians to practice complex procedures—such as catheterization and valve interventions—in risk-free environments. AR overlays can guide operators during live interventions, enhancing precision and reducing complications.

For patients, VR-based rehabilitation and stress reduction programs are emerging as supportive therapies, improving adherence and psychological well-being. AR tools also assist in preoperative planning by creating 3D visualizations of patient-specific anatomy. This track will highlight pioneering applications of VR and AR in cardiology, discussing implementation challenges, costs, and opportunities for scaling. Participants will gain insights into how immersive technologies could improve training, enhance procedural safety, and support patient recovery.

Bioprinting has opened exciting avenues in regenerative cardiology by enabling the creation of patient-specific cardiac tissues. Using stem cells and biomaterials, researchers can fabricate 3D constructs that mimic native myocardium, offering potential solutions for drug testing, disease modeling, and eventually heart tissue replacement. Unlike traditional tissue engineering, bioprinting provides unparalleled precision in replicating structural and functional properties of cardiac tissues.

Preclinical studies have demonstrated bioprinted patches capable of integrating with host myocardium, restoring contractility, and improving perfusion. While challenges such as vascularization, scalability, and regulatory approval remain, progress is accelerating. This track will showcase advances in bioprinting for cardiac applications, from bench to bedside. Attendees will explore the promise of engineered tissues in repairing myocardial injury, reducing transplant dependence, and ushering in a new era of personalized cardiac regeneration

Peripartum cardiomyopathy (PPCM) is a unique form of heart failure that occurs during late pregnancy or the postpartum period, often presenting with dilated cardiomyopathy and reduced ejection fraction. The etiology is multifactorial, involving vascular, inflammatory, and hormonal factors, including prolactin cleavage and oxidative stress. PPCM remains underdiagnosed due to symptom overlap with normal pregnancy changes, leading to delays in care and poor outcomes in severe cases.

Growing awareness has highlighted the importance of sex-specific cardiovascular research and tailored care strategies for women. Management includes standard heart failure therapies, but novel approaches such as bromocriptine are being studied for their role in modulating prolactin pathways. This track will discuss the pathophysiology, diagnostic challenges, and treatment advances in PPCM, while situating it within the broader context of women’s cardiovascular health. The session will emphasize the need for early recognition, multidisciplinary care, and global strategies to improve outcomes in affected women.

Cardiovascular disease remains the leading cause of death worldwide, and rural and underserved populations experience disproportionately higher burdens due to limited healthcare access, socioeconomic disparities, and scarcity of specialists. Geographic barriers, inadequate emergency services, and a lack of preventive care contribute to delayed diagnosis and poor outcomes in heart failure and angina. Social determinants of health—such as education, income, and lifestyle factors—further compound these challenges.

Innovative strategies, including mobile health clinics, telemedicine, and community health worker programs, are showing promise in extending cardiovascular care to underserved populations. Policy-driven interventions, workforce training, and digital health integration are also critical to closing care gaps. This track will explore real-world solutions, highlight success stories from different regions, and discuss scalable models for equitable cardiovascular care delivery. Attendees will gain insights into building sustainable systems that address both medical and social needs of vulnerable populations.

As heart failure progresses to advanced stages, symptom burden, hospitalizations, and mortality rise significantly. Traditional disease-focused care often overlooks quality of life and the complex physical, emotional, and spiritual needs of patients and families. Palliative care, integrated early into the management of advanced heart failure, addresses symptom control, goals-of-care discussions, and psychosocial support while continuing evidence-based therapies.

Emerging models advocate for collaborative care involving cardiologists, palliative specialists, and primary care providers. Interventions such as home-based palliative programs and telepalliative support are expanding access and improving patient satisfaction. This track will highlight strategies for integrating palliative principles into heart failure management, discuss ethical dilemmas around device deactivation and transplantation, and emphasize the importance of shared decision-making. Attendees will gain tools to balance prolonging life with enhancing its quality in patients facing advanced disease.

Psychological health is intimately linked to cardiovascular outcomes. Depression and anxiety are highly prevalent among patients with angina and heart failure, often worsening adherence, lifestyle management, and prognosis. Biological mechanisms such as heightened sympathetic activity, inflammation, and altered platelet function further reinforce the heart–mind connection. Despite this, mental health frequently remains underdiagnosed and undertreated in cardiology practice.

Integrating psychological screening and interventions—such as cognitive-behavioral therapy, mindfulness programs, and pharmacotherapy—into cardiovascular care has been shown to improve outcomes. Digital mental health platforms and collaborative care models provide scalable solutions to support patients. This track will examine the bidirectional relationship between mental health and heart disease, review evidence-based interventions, and explore innovative models for holistic cardiac care. The session will highlight the need to view cardiovascular health not only through a biological lens but also through psychosocial well-being.

Exercise is widely recognized as cardioprotective, yet intensive or competitive athletics may unmask or exacerbate underlying cardiac conditions, including hypertrophic cardiomyopathy, arrhythmogenic syndromes, and premature coronary disease. Sudden cardiac death in athletes, though rare, underscores the importance of understanding exercise-induced cardiac risks. In addition, inappropriate exercise prescriptions for heart failure patients can worsen symptoms if not carefully tailored.

Sports cardiology has emerged as a subspecialty dedicated to optimizing safe exercise participation. Advances in screening, wearable monitoring, and personalized training regimens enable better risk stratification and management. This track will focus on balancing the benefits of exercise with the risks of overexertion, highlight strategies for athlete screening, and explore rehabilitation models that incorporate safe, structured activity for cardiac patients. Attendees will gain insights into the evolving science of exercise prescription in both athletes and cardiovascular patients.

Cardiovascular disease rarely occurs in isolation; it frequently intersects with neurological and metabolic disorders, creating complex clinical syndromes. Conditions such as diabetes, stroke, and cognitive impairment share overlapping pathophysiological mechanisms—including inflammation, oxidative stress, and vascular dysfunction—that accelerate disease progression. Heart–brain–metabolic interactions are increasingly recognized as critical in determining patient outcomes.

Cross-disciplinary collaboration is essential to address these interconnected conditions. Integrated care models, joint research initiatives, and multidisciplinary clinics are paving the way for more holistic management. This track will highlight advances in understanding shared pathways, explore emerging therapies with cross-system benefits, and showcase models of collaborative care. Attendees will appreciate how bridging cardiology, neurology, and metabolism fosters comprehensive strategies to improve outcomes in patients with complex comorbidities.